Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
GSK, Idenix Ink Collaboration
by Rick Mullin
February 16, 2009
| A version of this story appeared in
Volume 87, Issue 7
GlaxoSmithKline has agreed to pay Cambridge, Mass.-based Idenix up to $450 million in a licensing agreement that will give GSK exclusive worldwide rights to IDX899, a novel nonnucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development for treatment of HIV/AIDS. IDX899 is being developed to address the increasing prevalence of viral resistance and side effects in the NNRTI drug class. Under the terms of the agreement, GSK will pay Idenix $34 million up front and as much as $416 million in development, regulatory, and sales milestones.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X